Ono Pharmaceutical Co Ltd 2013 SR
The report outlines Ono Pharmaceutical's CSR activities for the 2012 fiscal year, focusing on six priority areas: corporate governance, innovative drug development, human resources, the environment, fair operating practices, and society. Key highlights include the establishment of a new CSR Committee and the transition from an environmental report to a comprehensive CSR report. The company emphasizes its 'Compound-Orient' drug discovery approach and reports on progress in global clinical developments. Environmental initiatives focused on reducing CO2 emissions and waste, while social efforts included support for dementia patients and community involvement.
Company: Ono Pharmaceutical Co Ltd
Sector: Health Care
Country: Japan
Year: 2013
Type: SR
Pages: 19
Ono Pharmaceutical Co Ltd
CSR Report
The report outlines Ono Pharmaceutical's CSR activities for the 2012 fiscal year, focusing on six priority areas: corporate governance, innovative drug development, human resources, the environment, fair operating practices, and society. Key highlights include the establishment of a new CSR Committee and the transition from an environmental report to a comprehensive CSR report. The company emphasizes its 'Compound-Orient' drug discovery approach and reports on progress in global clinical developments. Environmental initiatives focused on reducing CO2 emissions and waste, while social efforts included support for dementia patients and community involvement.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2013
Reporting Period
Apr 1, 2012 - Mar 31, 2013
Fiscal Year
2012
Published
Nov 1, 2013
Type
Sustainability Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Other Standards
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Energy Consumption
Water Consumption
Total Waste
Employees